
CAS 1133819-87-0
:Formula:C19H17NO5S
InChI:InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23)
InChI key:YAUMOGALQJYOJQ-UHFFFAOYSA-N
SMILES:COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
Found 7 products.
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
5-(4-(2-(3-Methoxyphenyl)-2-Oxoethoxy)Benzyl)Thiazolidine-2,4-Dione
CAS:5-(4-(2-(3-Methoxyphenyl)-2-Oxoethoxy)Benzyl)Thiazolidine-2,4-DioneFormula:C19H17NO5SPurity:98%Molecular weight:371.41Azemiglitazone
CAS:Azemiglitazone (MSDC 0602) is an insulin sensitizer potentially for the treatment of diabetes.Formula:C19H17NO5SPurity:98.29% - 99.60%Color and Shape:White SolidMolecular weight:371.4075-(4-(2-(3-Methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dione
CAS:5-(4-(2-(3-Methoxyphenyl)-2-oxoethoxy)benzyl)thiazolidine-2,4-dioneFormula:C19H17NO5SPurity:98+%Molecular weight:371.41MSDC-0602
CAS:MSDC-0602 is a novel antidiabetic drug that has been shown to inhibit the uptake of glucose by adipose tissues. This drug also stimulates mitochondrial function and increases the capacity of human liver cells to metabolize fatty acids. MSDC-0602 is currently in clinical trials for use in patients with hepatic steatosis, diabetes, or cancer. It is hoped that this drug will be effective against these diseases due to its ability to increase the uptake of glucose by liver cells and adipose tissues and its stimulation of mitochondrial function.
Formula:C19H17NO5SPurity:Min. 95%Molecular weight:371.41 g/mol





